Dose escalation periods: When increasing from 0.25 mg to 0.5 mg (typically after 4 weeks), and subsequently to 1 mg or 2 mg if required, patients may experience a temporary resurgence of digestive symptoms
SDS / MSDS Safety and handling document available for operational review
Clinical and preclinical studies have revealed that AKI is a complex systemic disease with effects on virtually every organ 2 , including the lung 3,4 , heart 5,6 , liver 7,8 , brain 9 , and intestine 10
GLP-1s are actually simpler in many wayssubcutaneous injection, predictable titration schedule, manageable side effect profile (mostly GI: nausea, occasional vomiting)
Back in 1992, a doctor named John Eng made a very unusual discovery